Tumor bacteria in triple-negative breast cancer treatment response
Part of Cancer, Skin clinical trials.
This study looks at the bacteria found in the tumor to see if they affect how well chemotherapy or immunotherapy works in treating triple-negative breast cancer. The goal is to find ways to predict treatment response and improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female
- You are 18 years old or older
- You have been diagnosed with triple-negative breast cancer
- You are about to receive chemotherapy or a combination of chemo and immunotherapy before surgery
- You have not had chemotherapy before
- You have not taken antibiotics in the 10 days before your tumor sample is collected
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how breast cancer changes while you are receiving chemotherapy or targeted therapy before surgery. The goal is to better understand which treatments work best for different types of breast cancer.
This study uses a computer (AI) to read results from blood tests to look for signs of remaining triple-negative breast cancer, before and/or after surgery. It may help doctors better detect residual tumor and guide follow-up care.
This trial studies a simple blood test that may predict how well your body responds to chemotherapy plus immunotherapy before surgery for triple-negative breast cancer. The goal is to use these clues to personalize your treatment in the future.
This study looks at how breast cancer cells change during chemotherapy and immunotherapy before surgery. By analyzing tumor samples taken during treatment, doctors hope to find early signs of whether the treatment is working, which could lead to better-personalized care for people with triple negative or high-risk luminal breast cancer.
This study looks at how your diet and the natural bacteria in your gut (microbiome) may affect how well chemotherapy and immunotherapy work for early-stage triple-negative breast cancer. By participating, you may help doctors understand if certain gut bacteria can improve treatment outcomes.
This trial tests whether a treatment that targets your gut bacteria (microbiome) can help fight triple-negative breast cancer before surgery. It is for people with newly diagnosed, untreated triple-negative breast cancer that has not spread far.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.